Cilt 4, Sayı 2, Sayfalar 12 - 17 2017-02-28

Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease

Fatemeh Khaki Khatibi [1] , Soheila Gafarzadeh Giaci [2]

186 158

Objective: Coronary artery disease (CAD) is one of the major causes of mortality in the world. This indicates the need for identifying biomarkers of CAD diagnosis. Plasminogen as an inactive precursor of the protolithic enzyme plasmin initiates the dissolution of fibrin and consequently lysis of thrombus. Impaired fibrinolysis may cause CAD. This study was aimed to evaluate serum Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP complex) and Plasminogen in CAD patients compared to control group.

Materials and Methods: A total of 45 patients with CAD and 45 healthy matched subjects were enrolled. Plasma fibrinogen levels were measured using a commercially available kit according to the Clauss method. PAP and other of parameters were measured using the ELISA, immune enzymatic method according to the manufacturer’s instructions (Bioassay technology Laboratory, Instrumentation Laboratory, Shang high, china).

Results: Plasma levels of Fibrinogen were significantly higher in patient groups than control groups. PAP and Plasminogen were significantly lower in patient groups in comparison with controls. The correlations between plasma levels of the markers were not significant.

Conclusion: It is concluded that plasma level of fibrinogen is increased in CAD and plasma levels of plasminogen and plasmin is decreased in CAD, which represent a pathogenic factor for atherosclerosis compared with healthy subjects. Also we recommend the use of these biomarkers as a diagnostic factor for CAD patients. These finding suggested plasma levels of Fibrinogen, PAP and Plasminogen may be useful for early diagnosis of CAD.

Fibrinogen,Plasmin/a2-Anti-Plasmin complex,Plasminogen,Coronary Artery Disease,Diabetes,Smoker
  • 1. Leeson CPM, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circulation research. 2002;90(11):1153-8. doi: 10.1161/01.RES.0000020562.07492.D4.
  • 2. Naderi GA, Sarrafzadegan N, Boshtam M, Asgari S, Afyooni A, Jalali A, et al. The situation of new risk factors of cardiovascular disease in urban population of Isfahan. Journal of Kerman University of Medical Sciences. 2004;11(1):28-35.
  • 3. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. New England Journal of Medicine. 2012;366(1):54-63. doi: 10.1056/nejmra1112570.
  • 4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine. 2005;352(16):1685-95. doi: 10.1056/NEJMra043430.
  • 5. Lima LM, Carvalho MDG, Sousa MDO. Plasminogen and fibrinogen plasma levels in coronary artery disease. Revista brasileira de hematologia hemoterapia. 2012;34(4):298-301. doi: 10.5581/1516-8484.20120075.
  • 6. Ogston CM, Ogston D. Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease. Journal of clinical pathology. 1966;19(4):352-6.
  • 7. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clinics in haematology. 1986;15(2):355-70.
  • 8. Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arteriosclerosis thrombosis vascular biology. 1999;19(3):499-504.
  • 9. Kamath S, Lip G. Fibrinogen: biochemistry, epidemiology and determinants. Qjm. 2003;96(10):711-29.
  • 10. Undas A, Ariens RAS. Fibrin clot structure and function a role in the pathophysiology of arterial and venous thromboembolic diseases. Arteriosclerosis thrombosis vascular biology. 2011;31(12):e88-e99. doi: 10.1161/ATVBAHA.111.230631.
  • 11. Ross R. Cell biology of atherosclerosis. Annual Review of Physiology. 1995;57(1):791-804.
  • 12. Libby P. Vascular biology of atherosclerosis: overview and state of the art. The American journal of cardiology. 2003;91(3):3-6.
  • 13. George SJ, Johnson J. Atherosclerosis: molecular and cellular mechanisms. John Wiley & Sons. 2010;157. doi: 10.1002/9783527629589.
  • 14. Papageorgiou N, Tousoulis D, Siasos G, Stefanadis C. Is fibrinogen a marker of inflammation in coronary artery disease. Hellenic J Cardiol. 2010;51(1):1-9.
  • 15. Tatli E, Ozcelik F, Aktoz M. Plasma fibrinogen level may predict critical coronary artery stenosis in young adults with myocardial infarction. Cardiology journal. 2009;16(4):317-20.
  • 16. Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgarde F. Influence of Plasma Fibrinogen Levels on the Incidence of Myocardial Infarction and Death Is Modified by Other Inflammation-Sensitive Proteins A Long-Term Cohort Study. Arteriosclerosis thrombosis vascular biology. 2001;21(3):452-8.
  • 17. Reinhart WH. Fibrinogen-marker or mediator of vascular disease?. Vascular Medicine. 2003;8(3):211-6.
  • 18. Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thrombosis Haemostasis. 2005;3(8):1618-27. doi: 10.1111/j.1538-7836.2005.01416.x.
  • 19. Wilhelmsen L, Svardsudd K, Korsanbengtsen K, Larsson B, Welin L, Tibblin GS. Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine. 1984;311(8):501-5. doi: 10.1056/NEJM198408233110804.
  • 20. Acevedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. American heart journal. 2002;143(2):277-82.
  • 21. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. Jama. 1987;258(9):1183-6.
  • 22. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease the atherogene study. Arteriosclerosis thrombosis vascular biology. 2006;26(12):2793-9. doi: 10.1161/01.ATV.0000249406.92992.0d.
  • 23. Mosesson MW. Fibrinogen and fibrin structure and functions. J Throm Haemostasis. 2005;3(8):1894-904. doi: 10.1111/j.1538-7836.2005.01365.x.
  • 24. Booth NA. Fibrinolysis and thrombosis. Best Practice Res Clin Haematology. 1999; 12(3):423-33.
  • 25. Meltzer ME, Doggen CJM, Degroot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010;116(4):529-36. doi: 10.1182/blood-2010-01-263103.
  • 26. Hoffmeister A, Rothenbacher D, Khuseyinova N, Brenner H, Koenig W. Plasminogen levels and risk of coronary artery disease. The American journal of cardiology. 2002;90(10):1168-70.
  • 27. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, et al. Fibrinolytic Activation Markers Predict Myocardial Infarction in the Elderly The Cardiovascular Health Study. Arteriosclerosis thrombosis vascular biology. 1999;19(3):493-8.
  • 28. Redondo M, Carroll VA, Mauron T, Biasiutti FD, Binder BR, Lammle B, et al. Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-[alpha] 2-antiplasmin complex is an independent predictor of coronary re-events. Blood coagulation fibrinolysis. 2001;12(1):17-24.
  • 29. Coull BM, Beamer N, Degarmo P, Sexton G, Nordt F, Knox R, et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke. 1991;22(2):162-8.
  • 30. Yaghoubi AR, Ghojazadeh M, Abolhasani S, Alikhah H, Khaki Khatibi F. Correlation of Serum levels of Vitronectin, Malondialdehyde and hs-CRP With Disease Severity in Coronary Artery Disease. J Cardiovasc Thorac Res. 2015;7(4):113-7. doi: 10.15171/jcvtr.2015.24.
Konular Sağlık Bilimleri
Dergi Bölümü Orjinal Makale
Yazarlar

Yazar: Fatemeh Khaki Khatibi
E-posta: fatemehkhakikhatibi@yahoo.com
Kurum: Drug Applied Research Center and Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Ülke: Iran


Yazar: Soheila Gafarzadeh Giaci
E-posta: fatemehkhakikhatibi@yahoo.com
Kurum: Research Committee and Higher Education Institute of Rab-Rashidi, Tabriz, Iran
Ülke: Iran


Bibtex @araştırma makalesi { msd291365, journal = {Medical Science and Discovery}, issn = {2148-6832}, address = {Lycia Press Inc.}, year = {2017}, volume = {4}, pages = {12 - 17}, doi = {10.17546/msd.291365}, title = {Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease}, language = {en}, key = {cite}, author = {Gafarzadeh Giaci, Soheila and Khaki Khatibi, Fatemeh} }
APA Khaki Khatibi, F , Gafarzadeh Giaci, S . (2017). Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease. Medical Science and Discovery, 4 (2), 12-17. DOI: 10.17546/msd.291365
MLA Khaki Khatibi, F , Gafarzadeh Giaci, S . "Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease". Medical Science and Discovery 4 (2017): 12-17 <http://dergipark.gov.tr/msd/issue/27740/291365>
Chicago Khaki Khatibi, F , Gafarzadeh Giaci, S . "Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease". Medical Science and Discovery 4 (2017): 12-17
RIS TY - JOUR T1 - Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease AU - Fatemeh Khaki Khatibi , Soheila Gafarzadeh Giaci Y1 - 2017 PY - 2017 N1 - doi: 10.17546/msd.291365 DO - 10.17546/msd.291365 T2 - Medical Science and Discovery JF - Journal JO - JOR SP - 12 EP - 17 VL - 4 IS - 2 SN - 2148-6832-2148-6832 M3 - doi: 10.17546/msd.291365 UR - http://dx.doi.org/10.17546/msd.291365 Y2 - 2017 ER -
EndNote %0 Medical Science and Discovery Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease %A Fatemeh Khaki Khatibi , Soheila Gafarzadeh Giaci %T Correlation of Plasma Fibrinogen, Plasmin/a2-Anti-Plasmin complex (PAP Complex) and Plasminogen in Non-Smoker and Diabetic Patients with Coronary Artery Disease %D 2017 %J Medical Science and Discovery %P 2148-6832-2148-6832 %V 4 %N 2 %R doi: 10.17546/msd.291365 %U 10.17546/msd.291365